Ionis, AstraZeneca Team Up to Further Develop Eplontersen

Ionis, AstraZeneca Team Up to Further Develop Eplontersen

314070

Ionis, AstraZeneca Team Up to Further Develop Eplontersen

Ionis Pharmaceuticals has entered into a collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis’ investigational therapy to treat transthyretin amyloidosis (ATTR). ATTR amyloidosis is a group of conditions characterized by the formation of toxic aggregates or clumps of the TTR protein that build up in organs and tissues, including the heart and nerves. Familial amyloid polyneuropathy (FAP) is a form of ATTR amyloidosis caused by inherited mutations in the TTR gene, which encodes for the…

You must be logged in to read/download the full post.